Literature DB >> 12166897

Immunohistochemical study of endothelin-1 and matrix metalloproteinases in plexogenic pulmonary arteriopathy.

Kazuhiro Matsui1, Yasuo Takano, Zu-Xi Yu, Joanne Eunhee Suh Hi, William G Stetler-Stevenson, William D Travis, Victor J Ferrans.   

Abstract

The matrix metalloproteinases (MMPs) and endothelin-1, a potent vasoconstrictor and mitogen for smooth muscle cells, have been shown to be involved in the pathogenesis of various vascular disorders. However, the expression of endothelin-1 and the activation of MMPs have not been fully evaluated in plexogenic pulmonary arteriopathy (PPA). Immunohistochemical and confocal microscopic studies were conducted to evaluate the reactivity of lung tissue from six patients with pulmonary hypertension for alpha-smooth muscle actin (alpha-SMA), desmin, vimentin, factor VIII, endothelin-1, various types of MMPs (MMP-1, MMP-2, MMP-3, MMP-7 and MMP-9), membrane type-MMPs (MT-MMPs), tissue inhibitors of MMPs (TIMPs), and type IV collagen. Four major arterial morphological abnormalities were recognized in PPA: muscularization of pulmonary arterioles, onion-skin lesions, cellular and mature plexiform lesions, and atheromas in elastic pulmonary arteries. Reactivity for MMP-2 and MT-1-MMP was found in endothelial cells and, to a lesser extent, in myofibroblasts proliferating in various lesions of PPA. Increased expression of endothelin-1 was observed in the latter cells and in endothelial cells. Some myofibroblasts were positive for MMP-3 and MMP-7 in the vascular lesions except for mature plexiform lesions. MMP-1, MMP-9 and TIMP-2 tended to be positive only in the atheromatous lesions. Staining for type IV collagen showed focal thinning and discontinuities of the endothelial basement membrane in plexiform lesions. This study demonstrates colocalization of MMP-2 with MT-1-MMP and increased expression of endothelin-1 in various arterial lesions of PPA. These changes may play important roles in the remodeling of arterial structures, particularly of basement membranes, in this disorder.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12166897     DOI: 10.1078/0344-0338-00273

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  11 in total

Review 1.  Pathology of pulmonary hypertension.

Authors:  Rubin M Tuder; John C Marecki; Amy Richter; Iwona Fijalkowska; Sonia Flores
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

2.  Relationship between matrix metalloproteinase-3 serum level and pulmonary artery systolic pressure in patients with rheumatoid arthritis.

Authors:  Tetsuro Sugiura; Mikio Kamioka; Shigeo Yamanaka; Taisuke Hisahara; Yoko Hirakawa; Yoshihisa Matsumura
Journal:  Heart Vessels       Date:  2017-08-21       Impact factor: 2.037

Review 3.  Microvessel mechanobiology in pulmonary arterial hypertension: cause and effect.

Authors:  Nathaniel C Bloodworth; James D West; W David Merryman
Journal:  Hypertension       Date:  2014-12-22       Impact factor: 10.190

4.  Compartment-specific expression of collagens and their processing enzymes in intrapulmonary arteries of IPAH patients.

Authors:  Julia Hoffmann; Leigh M Marsh; Mario Pieper; Elvira Stacher; Bahil Ghanim; Gabor Kovacs; Peter König; Heinrike Wilkens; Hans Michael Haitchi; Gerald Hoefler; Walter Klepetko; Horst Olschewski; Andrea Olschewski; Grazyna Kwapiszewska
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-04-03       Impact factor: 5.464

5.  Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension.

Authors:  Ari L Zaiman; Megan Podowski; Satya Medicherla; Kimberley Gordy; Fang Xu; Lijie Zhen; Larissa A Shimoda; Enid Neptune; Linda Higgins; Alison Murphy; Sarvajit Chakravarty; Andrew Protter; Pravin B Sehgal; Hunter C Champion; Rubin M Tuder
Journal:  Am J Respir Crit Care Med       Date:  2008-01-17       Impact factor: 21.405

6.  Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.

Authors:  Ellena J Growcott; Karen G Spink; Xiaohui Ren; Saliha Afzal; Kathy H Banner; John Wharton
Journal:  Respir Res       Date:  2006-01-19

Review 7.  Mechanobiological Feedback in Pulmonary Vascular Disease.

Authors:  Paul B Dieffenbach; Marcy Maracle; Daniel J Tschumperlin; Laura E Fredenburgh
Journal:  Front Physiol       Date:  2018-07-25       Impact factor: 4.566

8.  The role of matrix metalloproteinases in patients with pulmonary hypertension: data from a prospective study.

Authors:  Adriana Marc; Calin Pop; Adela-Viviana Sitar-Taut; Liviuta Budisan; Ioana Berindan-Neagoe; Dana Pop
Journal:  BMC Cardiovasc Disord       Date:  2021-12-20       Impact factor: 2.298

9.  Ambrisentan for the treatment of pulmonary arterial hypertension.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

Review 10.  Endothelial Basement Membrane Components and Their Products, Matrikines: Active Drivers of Pulmonary Hypertension?

Authors:  Ayse Ceren Mutgan; Katharina Jandl; Grazyna Kwapiszewska
Journal:  Cells       Date:  2020-09-03       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.